0000000000024094

AUTHOR

Alessandro Ciresi

showing 104 related works from this author

Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children

2016

PURPOSE: The effect of growth hormone (GH) on adipose tissue and the role of adipokines in modulating metabolism are documented, but with discordant data. Our aim was to evaluate the impact of GH treatment on a series of selected adipokines known to have a metabolic role and poorly investigated in this setting. METHODS: This is a prospective study. Thirty-one prepubertal children (25 M, 6 F; aged 8.5 ± 1.6 years) with isolated GH deficiency treated with GH for at least 12 months and 30 matched controls were evaluated. Auxological and metabolic parameters, insulin sensitivity indexes, leptin, soluble leptin receptor, adiponectin, visfatin, resistin, omentin, adipocyte fatty acid-binding prot…

0301 basic medicineLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokineAdipose tissue030209 endocrinology & metabolismEnzyme-Linked Immunosorbent AssayGPI-Linked ProteinsAdipokines; Children; Growth hormone; Insulin sensitivitySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineAdipocyteLectinsAdipokinemedicineHumansResistinProspective StudiesChildNicotinamide PhosphoribosyltransferaseChildrenGrowth hormoneGrowth DisordersLeptin receptorAdiponectinbusiness.industryHuman Growth HormoneLeptinInsulinInsulin sensitivityHormones030104 developmental biologyEndocrinologychemistryCase-Control StudiesChild PreschoolCytokinesResistinFemalebusinessBiomarkers
researchProduct

Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations

2015

Objective: The studies that have extensively evaluated the relation between adipokines and metabolic parameters in acromegaly treatment are quite discordant. We aimed to evaluate and correlate a set of selected adipokines, known to have a metabolic role, with the disease activity, metabolic status and treatment modalities. Design: Data of 56 consecutive acromegalic patients (31 M and 25 F; aged 54 ± 12 years), admitted to the section of Endocrinology of the University of Palermo during the years 2005-2014, including 16 newly diagnosed untreated (ND), 21 during therapy with somatostatin analogues (SA), 12 with pegvisomant (PE) and 7 after surgical treatment (SU), grouped into uncontrolled (g…

AdultLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismAdipokineFatty Acids NonesterifiedSettore MED/13 - EndocrinologiaInsulin resistanceEndocrinologyAcromegaly; Adipokines; Growth hormone; Endocrinology; Endocrinology Diabetes and MetabolismAdipokinesInternal medicineAdipokineAcromegalyMedicineHumansNicotinamide PhosphoribosyltransferaseGrowth hormoneTriglyceridesAdiposityAgedLeptin receptorAdiponectinbusiness.industryLeptinCholesterol HDLMiddle Agedmedicine.diseaseEndocrinologyCross-Sectional StudiesPegvisomantAcromegalyCytokinesResistinFemaleInsulin ResistancebusinessBiomarkersmedicine.drug
researchProduct

Predictors of microvascular complications in type 1 diabetic patients at onset: The role of metabolic memory

2011

Background Several epidemiological studies showed a close association between metabolic control and microvascular complications in type 1 Diabetes Mellitus (T1DM). The aim of our longitudinal observational study was to evaluate the predictive role of the main clinical and biochemical parameters in determining microvascular complications. Methods 376 T1DM patients, hospitalized in our division from 1991 to 2005 (mean follow-up = 10.93 ± 4.26 years) were studied. Stepwise Cox regression analysis was used to identify the influence of residual ß-cell function, ß-cell autoimmunity, HbA1c levels and other clinical and laboratory parameters in the development of microalbuminuria and retinopathy. R…

Malemedicine.medical_specialtyAdolescentendocrine system diseasesSettore MED/13 - EndocrinologiaNephropathyYoung AdultPredictive Value of TestsInsulin-Secreting CellsInternal medicineDiabetes mellitusInternal MedicinemedicineAlbuminuriaHumansDiabetic NephropathiesLongitudinal StudiesAge of OnsetChildAutoantibodiesProportional Hazards ModelsGlycated HemoglobinInpatientsType 1 diabetesDiabetic Retinopathybusiness.industryMicrocirculationMicroangiopathyType 1 diabetes microvascular Complicationsnutritional and metabolic diseasesmedicine.diseaseSurgeryDiabetes Mellitus Type 1Metabolic control analysisPredictive value of testsFemaleMicroalbuminuriaAge of onsetbusinessDiabetic AngiopathiesFollow-Up StudiesEuropean Journal of Internal Medicine
researchProduct

Early Lung Function Abnormalities in Acromegaly.

2014

BACKGROUND: Acromegaly is an insidious disorder caused by a pituitary growth hormone (GH)-secreting adenoma resulting in high circulating levels of GH and insulin-like growth factor I (IGF-I). Respiratory disorders are common complications in acromegaly, and can severely impact on quality of life, eventually affecting mortality. OBJECTIVES: The present study aimed to explore structural and functional lung alterations of acromegalic subjects. METHODS: We enrolled 10 consecutive patients (M/F: 5/5) affected by acromegaly. In all patients, magnetic resonance imaging (MRI) revealed the presence of pituitary tumor. All patients underwent clinical, lung functional, biological, and radiological as…

AdultLung DiseasesMalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyTime FactorsAdenomaVital CapacitySettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyspirometry dyspnea acromegalySettore MED/13 - EndocrinologiaPredictive Value of TestsDLCOForced Expiratory VolumeDiffusing capacityInternal medicineAcromegalymedicineHumansLung volumesRespiratory systemLungAgedLungbusiness.industryPituitary tumorsMiddle Agedrespiratory systemmedicine.diseaseMagnetic Resonance Imagingrespiratory tract diseasesRadiographyEarly Diagnosismedicine.anatomical_structureCase-Control StudiesPulmonary Diffusing CapacityFemaleGrowth Hormone-Secreting Pituitary AdenomaLung Volume Measurementsbusiness
researchProduct

Lacrimal glands herniation in patients with Graves’ Ophthalmopathy: an effective MRI-derived marker of disease activity

2017

Aims and objectives Methods and materials Results Conclusion Personal information References

InflammationHead and neckStaginggenetic structuresEndocrine disordersEyesMREyes Head and neck MR Diagnostic procedure Staging Endocrine disorders InflammationDiagnostic procedure
researchProduct

Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency

2007

Objective: GH replacement therapy in children with GH deficiency (GHD) mainly promotes linear growth. Not only have very few studies fully analyzed the metabolic consequences of GH therapy, but also the question as to whether GH may affect adipokine secretion has been insufficiently investigated. Our aim was to study the effects of GH replacement therapy on auxological data, lipid and glycemic profiles, insulin homeostasis (HOMA-IR) and serum adipokines in children. Methods: This was a 1-year prospective study. Thirty-four GHD children (11.6 ± 2.6 years) and thirty healthy matched controls were enrolled. Children affected by GHD were studied both before beginning continuous GH replacement t…

LeptinMalemedicine.medical_specialtyTime FactorsAdolescentHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokineBiologyBody Mass IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundEndocrinologyInternal medicinemedicineHumansInsulinInsulin-Like Growth Factor IChildGrowth DisordersTriglyceridesGlycemicmedicine.diagnostic_testAdiponectinHuman Growth HormoneCholesterolLeptinInsulinBody WeightCholesterol LDLGeneral MedicineBody HeightTreatment OutcomeEndocrinologychemistryTransgender hormone therapyFemaleAdiponectinLipid profileGH METABOLISM ADIPOKINESEuropean Journal of Endocrinology
researchProduct

Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency.

2016

AbstractGrowth hormone (GH) plays a role in the regulation of ovarian function but there are limited data in women with GH deficiency (GHD). Our aim was to evaluate the features of polycystic ovarian syndrome (PCOS) in women with previous GHD.Data of 22 adolescents previously GH-treated (group A) were compared with those of 22 women with classical PCOS (group B) and 20 controls (group C).: Group A showed higher testosterone (p=0.048) and prevalence of menstrual irregularities (p<0.001) than group C. Compared to the group B, group A showed lower diastolic blood pressure (p=0.004), degree of hirsutism (p=0.005), testosterone (p=0.003) and prevalence of polycsytic ovaries (POC) morphology (…

MaleHirsutismmedicine.medical_specialtyAdolescentChildhood growthEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGroup AGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinePrevalenceHumansMedicineTestosteroneProspective StudiesChildGrowth DisordersMenstruation DisturbancesTestosteronehirsutism030219 obstetrics & reproductive medicineEstradiolHuman Growth Hormonebusiness.industryPrognosismedicine.diseaseGrowth hormone polycystic ovarian syndromeEndocrinologyBlood pressureItalyCase-Control StudiesPediatrics Perinatology and Child HealthFemaleHyperandrogenismbusinessBiomarkersGH DeficiencyFollow-Up StudiesPolycystic Ovary SyndromeHormone
researchProduct

More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children

2017

Objective. To evaluate whether two different regimens of weekly injections could lead to similar auxological and metabolic effects in children with growth hormone deficiency (GHD).Design. 32 GHD children (25 males, mean age 10.5 ± 2.2 yr) were randomly assigned to receive daily (group A, 16 patients) or TIW (group B, 16 patients) GHT for 12 months.Methods. Auxological parameters, insulin-like growth factor-I (IGF-I), glucose and insulin during OGTT, glycosylated hemoglobin (HbA1c), lipid profile, the oral disposition index (DIo), the homeostasis model assessment estimate of insulin resistance (Homa-IR), and the insulin sensitivity index (ISI).Results. After 12 months, both groups showed a s…

0301 basic medicinemedicine.medical_specialtyArticle SubjectEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismgrowth hormone deficiency childrenlcsh:Diseases of the endocrine glands. Clinical endocrinologyGroup BGrowth hormone deficiencySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicinemedicinelcsh:RC648-665medicine.diagnostic_testEndocrine and Autonomic Systemsbusiness.industryInsulinmedicine.diseaseGrowth hormone treatmentRegimen030104 developmental biologyEndocrinologyClinical StudyHemoglobinbusinessLipid profileInternational Journal of Endocrinology
researchProduct

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

The metabolic outcomes of growth hormone treatment in children are gender specific

2018

Objective To evaluate the impact of gender on the clinical and metabolic parameters in prepubertal growth hormone deficiency (GHD) children at diagnosis and during GH treatment (GHT). Design The data of 105 prepubertal children (61 males, 44 females, mean age 6.8 ± 0.7 years) affected by idiopathic GHD were retrospectively evaluated. Methods Body height, BMI, waist circumference (WC), IGF-I, HbA1c, lipid profile, fasting and after-OGTT glucose and insulin levels, insulin sensitivity and secretion indices were evaluated at baseline and after 24 months of GHT. Results At baseline, no significant difference was found in all clinical, hormonal and metabolic parameters between males and females…

0301 basic medicinemedicine.medical_specialtyWaistEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiaGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologychildrenInternal medicineStatistical significanceInternal Medicinemedicinegenderinsulin sensitivitychildren; gender; growth hormone; insulin sensitivity; metabolismlcsh:RC648-665medicine.diagnostic_testbusiness.industryInsulinResearchnutritional and metabolic diseasesmedicine.diseaseGrowth hormone treatment030104 developmental biologyConcomitantgrowth hormoneLipid profilebusinessmetabolismHormoneEndocrine Connections
researchProduct

Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease

2017

Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications

Pituitary glandmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpasireotide cushing diseaseSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyDiabetes mellitusmedicineIn patientbusiness.industryPituitary ACTH hypersecretionRetrospective cohort studyCushing's diseasemedicine.diseasePasireotideSurgerymedicine.anatomical_structurechemistry030220 oncology & carcinogenesisPituitary surgerybusinessEndocrine
researchProduct

Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: Efficacy of octreotide therapy

2011

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryEndocrinology Diabetes and MetabolismTreatment outcomeOctreotideMagnetic resonance imagingmedicine.diseaseGastroenterologyGigantismSettore MED/13 - EndocrinologiaRemission inductionEndocrinologyEndocrinologygigantism octreotidePituitary adenomaInternal medicineMedicinebusinessmedicine.drug
researchProduct

Circulating Irisin Levels in Children With GH Deficiency Before and After 1 Year of GH Treatment.

2018

Abstract Purpose To evaluate circulating irisin levels in children with GH deficiency (GHD) and any relation with clinical and metabolic parameters. Patients Fifty-four prepubertal children (mean age, 7.4 ± 0.8 years) with idiopathic GHD treated with GH for at least 12 months and 31 healthy short children as control subjects. Methods Body height, body mass index (BMI), waist circumference (WC), IGF-I, HbA1c, lipid profile, fasting and after–oral glucose tolerance test glucose and insulin, insulin sensitivity indices, and irisin levels were evaluated at baseline and after 12 months of GH replacement (GHR). Results At baseline, children with GHD, in addition to having lower growth velocity (P…

0301 basic medicineMalemedicine.medical_specialtyWaistHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical Biochemistry030209 endocrinology & metabolismGrowth hormone receptorBiochemistrySettore MED/13 - EndocrinologiaGrowth hormone deficiencyBody Mass Index03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicinemedicineHumansProspective StudiesInsulin-Like Growth Factor IChildGrowth DisordersGlucose tolerance testmedicine.diagnostic_testbusiness.industryInsulinBiochemistry (medical)medicine.diseaseFibronectins030104 developmental biologyEndocrinologyTreatment OutcomeGrowth HormoneFemaleWaist CircumferenceLipid profilebusinessBody mass indexThe Journal of clinical endocrinology and metabolism
researchProduct

Cornea in acromegalic patients as a possible target of growth hormone action.

2010

Background: GH exerts its effects on many organs and the eye also seems to be a target site, although few authors have investigated the corneal thickness in patients with acromegaly. Aim: To perform a detailed ophthalmological evaluation in acromegalic patients, in relation to disease activity. Material and methods: Twenty-eight acromegalic patients (11 males, 17 females) and 22 voluntary healthy subjects underwent complete metabolic and ophthalmological evaluation, including retinal thickness (RT), central corneal thickness (CCT), and intraocular pressure values (IOP). Results: Significantly greater CCT values were found in all acromegalic patients in comparison with controls (567 vs 528.5…

Malemedicine.medical_specialtyIntraocular pressureacromegaly corneagenetic structuresEndocrinology Diabetes and MetabolismOcular hypertensionGrowth hormoneSettore MED/13 - EndocrinologiaCorneaBasal (phylogenetics)chemistry.chemical_compoundEndocrinologyCorneaInternal medicineOphthalmologyAcromegalymedicineAnimalsHumansIntraocular PressureMetabolic SyndromeSettore MED/30 - Malattie Apparato Visivobusiness.industryHuman Growth HormoneRetinalMiddle Agedmedicine.diseaseeye diseasesmedicine.anatomical_structureEndocrinologychemistryConcomitantAcromegalyFemaleOcular Hypertensionsense organsbusiness
researchProduct

Corneal thickness in children with growth hormone deficiency: The effect of GH treatment.

2014

Abstract OBJECTIVE: The eye represents a target site for GH action, although few data are available in patients with GH deficiency (GHD). Our aim was to evaluate central corneal thickness (CCT) and intraocular pressure (IOP) values in GHD children to assess the role played by GHD or GH treatment on these parameters. DESIGN: In 74 prepubertal GHD children (51M, 23F, aged 10.4±2.4years) we measured CCT and IOP before and after 12months of treatment. A baseline evaluation was also made in 50 healthy children matched for age, gender and body mass index. The study outcome considered CCT and IOP during treatment and their correlations with biochemical and auxological data. RESULTS: No difference …

Malegrowth hormone deficiencymedicine.medical_specialtyIntraocular pressurePediatricsgenetic structuresEndocrinology Diabetes and MetabolismGrowth hormone deficiencySettore MED/13 - EndocrinologiaCorneaEndocrinologyGH treatmentInternal medicineHumansMedicineIn patientCorneal thickneChildDwarfism PituitaryIntraocular PressureBaseline valuesHuman Growth Hormonegrowth hormone deficiency; Corneal thickness; GH treatmentbusiness.industryOrgan Sizemedicine.diseaseeye diseasesEndocrinologyTarget siteGh treatmentFemalesense organsbusinessBody mass indexGH Deficiency
researchProduct

Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients.

2012

Context: The visceral adiposity index (VAI) has proved to be a marker of visceral adipose dysfunction, strongly associated with insulin sensitivity in both the general and specific populations of patients at metabolic risk. Objective: The objective of the study was to test VAI as a useful tool to assess early metabolic risk in acromegaly. Patients: Twenty-four newly diagnosed acromegalic patients (11 women and 13 men, aged 54.9 ± 13.6 yr) were grouped into those with normal (group A, n = 13, 54.2%) and those with high VAI (group B, n = 11, 45.8%). Outcome Measures: Glucose, hemoglobin A1c, nadir and area under the curve (AUC) of GH (AUCGH) during the oral glucose tolerance test, AUCCpeptide…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryAdipokineContext (language use)Intra-Abdominal FatBiochemistrySettore MED/13 - EndocrinologiaEndocrinologyInsulin resistanceAdipokinesInternal medicineAcromegalymedicineAcromegaly Visceral Adiposity IndexHumansInsulin-Like Growth Factor IAdiposityAgedAdiponectinbusiness.industryHuman Growth HormoneLeptinBiochemistry (medical)Area under the curveMiddle Agedmedicine.diseaseEndocrinologyArea Under CurveAcromegalyFemaleMetabolic syndromeInsulin ResistancebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hor…

2012

OBJECTIVE: An increased prevalence of hematological abnormalities is reported in acromegaly, but to date no reports about the presence of the Janus Kinase (JAK) 2 mutation in acromegalic patients have been described. DESIGN: We report the complex clinical presentation of the unique case, never described, of acromegaly due to GH-secreting pituitary adenoma associated with JAK2 V617F mutation. RESULTS: The patient shows primary thrombocythemia and myelofibrosis, due to JAK2 V617F mutation, severe visceromegaly and a peculiar clinical course of the disease characterized by discrepant values of GH and IGF-1 during somatostatin analog (SA) treatment despite a significant reduction in pituitary a…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismGrowth hormone receptorAcromegaly HGH IGF-1GastroenterologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyPituitary adenomahemic and lymphatic diseasesInternal medicineAcromegalymedicineAnimalsHumansPituitary NeoplasmsInsulin-Like Growth Factor IRadiometryMyelofibrosisAgedJanus kinase 2biologyHuman Growth HormonePlatelet Countbusiness.industryJanus Kinase 2medicine.diseaseAcromegaly Growth hormone Insulin-like growth factor-1 Janus kinase 2 Growth hormone receptorEndocrinologyAcromegalyMutationPegvisomantbiology.proteinJanus kinasebusinessVisceromegalyFollow-Up StudiesThrombocythemia Essentialmedicine.drug
researchProduct

Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index

2015

The aim of the study is to clarify the relationship between adipose tissue dysfunction, metabolic profile and growth hormone (GH)/insulin-like growth factor (IGF)-I secretion in healthy adult subjects. We investigated the metabolic profile in a cohort of 231 consecutive healthy subjects in relation to GH, IGF-I levels, and visceral adiposity index (VAI). Anthropometric measures, lipid profile, and glucose and insulin levels during oral glucose tolerance test, Homa-IR and ISI Matsuda, IGF-I and GH peak after GHRH plus Arginine test were analyzed. The subjects with high VAI showed lower GH peak (22.8 ± 11.1 vs. 42.2 ± 21.3 µg/L; p = 0.049) and lower IGF-I (presented as IGF-I under normal rang…

AdultMaleRiskmedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissueIntra-Abdominal FatBiologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyMetabolic DiseasesInternal medicineDiabetes mellitusmedicineHealth Status IndicatorsHumansMetabolic riskInsulin-Like Growth Factor IProspective cohort studyGrowth hormoneSubclinical infectionGH deficiencymedicine.diagnostic_testHuman Growth HormoneInsulinGH deficiency; Growth hormone; Metabolic risk; Visceral adiposity; Endocrinology; Endocrinology Diabetes and MetabolismMiddle Agedmedicine.diseaseEndocrinologyBlood pressureCohortFemaleVisceral adiposityLipid profile
researchProduct

Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance.

2015

PURPOSE: Insulin resistance and compensatory hyperinsulinism are the predominant metabolic defects in polycystic ovary syndrome (PCOS). However, hyperinsulinism, as well as being compensatory, can also express a condition of reduced insulin clearance. Our aim was to evaluate the differences in insulin action and metabolism between women with PCOS (with normal glucose tolerance) and age- and BMI-matched women with prediabetes (without hyperandrogenism and ovulatory disorders). METHODS: 22 women with PCOS and 21 age/BMI-matched women with prediabetes were subjected to a Hyperinsulinemic-euglycemic clamp and an Oral Glucose tolerance Test (OGTT). Insulin sensitivity was assessed by the glucose…

Adultmedicine.medical_specialtyendocrine system diseasesAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentSettore MED/13 - EndocrinologiaPrediabetic StateYoung AdultEndocrinologyInsulin resistanceInternal medicineHyperinsulinismmedicineHumansInsulinPrediabetesbusiness.industryPolycystic ovary syndrome (PCOS)InsulinHyperandrogenismnutritional and metabolic diseasesGlucose clamp techniquemedicine.diseasePolycystic ovaryEndocrinologypolycystic ovary syndromeGlucose Clamp TechniqueFemaleInsulin ResistancebusinessHyperinsulinismPolycystic Ovary SyndromeJournal of endocrinological investigation
researchProduct

Adrenal morphology and function in acromegalic patients in relation to disease activity.

2009

Visceromegaly is a common consequence of acromegaly. However, few studies investigated the chronic effects of growth hormone on adrenal glands. Our aim was to evaluate adrenal morphology and function in a cohort of acromegalic patients in relation to disease activity. Twenty-six acromegalics (10 males and 16 females) and 21 healthy subjects were investigated. Gland morphology was evaluated by computerized axial tomography, measuring central, lateral, and medial adrenal segments. Uncontrolled acromegalics showed increased volume of all adrenal segments, higher urinary free cortisol (UFC), and lower morning adrenocorticotropic hormone in comparison with healthy subjects. However, normal corti…

AdultMaleHypothalamo-Hypophyseal Systemmedicine.medical_specialtyEndocrinology Diabetes and MetabolismPituitary-Adrenal SystemAdrenocorticotropic hormoneCardiovascular SystemSeverity of Illness IndexSettore MED/13 - EndocrinologiaEndocrinologyDiabetes mellitusInternal medicineAdrenal GlandsAcromegalymedicineHumansAgedMorningbusiness.industryAdrenal glandCase-control studyOrgan SizeMiddle Agedmedicine.diseaseEndocrinologymedicine.anatomical_structureAcromegaly Growth hormone Adrenal gland CortisolCase-Control StudiesDexamethasone suppression testAcromegalyDisease ProgressionFemalebusinessVisceromegaly
researchProduct

The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome

2017

Cushing syndrome (CS) is characterized by increased morbidity and mortality compared to the general population. However, there are patients who have more clinical aggressive forms than others. Aim of the study is to evaluate whether the degree of hypercortisolism, defined by the number of times urinary free cortisol (UFC) levels exceed the upper limit of the normal range (ULN), is related to the worsening of phenotypic features, as well as metabolic and cardiovascular parameters, in a cohort of CS patients. A cross-sectional study was conducted on 192 patients with active CS, consecutively presenting at the outpatients' clinic of the University Hospitals of Ancona, Naples, and Palermo. Pati…

AdultMalemedicine.medical_specialtyPediatricsHydrocortisoneEndocrinology Diabetes and MetabolismUrinary systemCushing hypercortisolismPopulationCushing syndrome severity030209 endocrinology & metabolismGastroenterologySeverity of Illness IndexDexamethasoneUrinary free cortisolSettore MED/13 - Endocrinologia03 medical and health sciencesCushing syndromeYoung Adult0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineUrinary free cortisolmedicineHumanseducationCushing SyndromeCushing syndrome comorbiditieeducation.field_of_studyS syndromebusiness.industryDegree of hypercortisolismMiddle Agedmedicine.diseaseCross-Sectional Studies030220 oncology & carcinogenesisDexamethasone suppression testCohortFemalebusiness
researchProduct

Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A…

2018

Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes.We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time.Although both groups showed a reduction…

Endocrinology Diabetes and MetabolismInternal MedicineAuthor CorrectionDiabetes Therapy
researchProduct

Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

2018

Purpose: To evaluate the effect of pasireotide on β-cell and adipose function in patients with Cushing’s disease (CD). Methods: Clinical and hormonal parameters, insulin secretion evaluated by HOMA-β and by the area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test and insulin sensitivity, evaluated by the euglycaemic hyperinsulinaemic clamp, were evaluated in 12 patients with active CD, before and after 6 and 12 months of pasireotide. In addition, a panel of adipokines including leptin (Ob), leptin/leptin receptor ratio (Ob/Ob-R ratio), adiponectin, resistin, visfatin, adipocyte fatty acid binding protein (AFABP) and non-esterified fatty acids (NEFAs) was evaluated at…

AdultBlood GlucoseMalemedicine.medical_specialtyDiabetes mellituInjections SubcutaneousEndocrinology Diabetes and MetabolismAdipose tissueAdipokine030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaCohort StudiesYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyAdipokinesInternal medicineDiabetes mellitusAdipokinemedicineHumansInsulinPituitary ACTH HypersecretionLeptin receptorAdiponectinbusiness.industryLeptinBody WeightMiddle AgedCushing’s diseasemedicine.diseaseInsulin sensitivityHormonesPasireotidePasireotideTreatment OutcomeEndocrinologychemistryFemaleResistinInsulin ResistanceSomatostatinbusiness
researchProduct

One-hour post-load plasma glucose level is associated with a worse metabolic profile in children with GH deficiency

2017

Purpose: In children, the plasma glucose value at 1 h (1hPG) during OGTT higher than 132.5 mg/dl is a predictor of alterations in glucose metabolism. We aimed to metabolically characterize GHD children according to 1hPG levels. Methods: Fifty-one GHD children (35 M, 16 F; mean age 8.6 years), grouped according to 1hPG, were evaluated at diagnosis and after 12 months of GH treatment (GHT) and compared with 50 matched controls at baseline. Auxological parameters, insulin-like growth factor-1 (IGF-1), glucose and insulin during OGTT, lipid profile, the oral disposition index (DIo), the homeostasis model assessment estimate of insulin resistance (Homa-IR), and the insulin sensitivity index (ISI…

Blood GlucoseMalemedicine.medical_specialtyTime FactorsTime FactorEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism030204 cardiovascular system & hematologyCarbohydrate metabolismSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceGH treatmentInternal medicineInsulin SecretionHumansInsulinMedicineChildDwarfism PituitaryGrowth hormoneGlucose tolerance testmedicine.diagnostic_testHuman Growth Hormonebusiness.industryCholesterolInsulinCase-control studynutritional and metabolic diseasesGlucose Tolerance TestInsulin sensitivitymedicine.diseaseMetabolismEndocrinologychemistryCase-Control StudiesChild PreschoolMetabolomeFemaleInsulin ResistanceCase-Control StudiebusinessLipid profileHomeostasisHumanJournal of Endocrinological Investigation
researchProduct

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month…

2017

INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes. METHODS: We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time. RESULTS: Altho…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineInternal MedicinemedicineGlycemicFramingham Risk Scorebusiness.industryLiraglutideBrief ReportInsulinDiabetesLiraglutideCardiovascular riskmedicine.diseaseliraglutide diabetesMetforminEndocrinologyBlood pressureVisceral adipositybusinessmedicine.drug
researchProduct

The Metabolic Profile in Active Acromegaly is Gender-Specific.

2012

CONTEXT: The sexual dimorphism of the somatotroph axis has been documented, but whether the acromegaly-related metabolic alterations are gender-dependent has never been investigated. OBJECTIVE: The aim of the study was to evaluate the impact of gender on the metabolic parameters in acromegaly. DESIGN: We conducted a retrospective, comparative, multicenter study. PATIENTS: The 307 newly diagnosed acromegalic patients included in the study were grouped by gender: 157 men (aged 48.01 ± 14.28 yr), and 150 women (aged 48.67 ± 14.95 yr; of which 77 were premenopausal and 73 postmenopausal). OUTCOME MEASUREMENTS: We measured each component of the metabolic syndrome (MS), hemoglobin A1c, the areas …

AdultBlood GlucoseMalemedicine.medical_specialtySomatotropic cellEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryContext (language use)Intra-Abdominal FatBiochemistrySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyInsulin resistanceInternal medicineAcromegalygendermedicineHumansInsulinAgedRetrospective StudiesSex Characteristicsbusiness.industryInsulinBiochemistry (medical)FastingMiddle Agedmedicine.diseasemetabolic profileObesitySexual dimorphismEndocrinologyAcromegalyMetabolomeFemaleMetabolic syndromeInsulin Resistancebusiness
researchProduct

Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study.

2012

To evaluate the metabolic effects of first-line somatostatin analogues or surgery in acromegaly. Retrospective, comparative, 12-month follow-up. Two hundred and thirty one patients (123 men, age 47.32 ± 14.63 years) with active acromegaly, first line treatments were somatostatin analogues in 151 (65.4%) and surgery in 80 (34.6%). Metabolic syndrome (MS) parameters, glucose, insulin and GH during oral glucose tolerance test, stimulated insulin sensitivity by insulin sensitivity index (ISI Matsuda), early and total insulin-secretion rate by insulinogenic index and AUC(INS), visceral adiposity function, expressed by visceral adipose index (VAI). Somatostatin analogues treatment improved all MS…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentsomatostatin analogueSettore MED/13 - EndocrinologiasurgeryYoung AdultEndocrinologyInternal medicineAcromegalyMedicineHumansYoung adultInsulin-Like Growth Factor IAgedRetrospective StudiesAged 80 and overbusiness.industryHuman Growth HormoneInsulinRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryFirst line treatmentSomatostatinEndocrinologyMetabolic effectsAcromegalyacromegaly; somatostatin analogues; metabolismFemaleMetabolic syndromebusinessSomatostatinmetabolismPituitary
researchProduct

High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement tr…

2014

PURPOSE: Although the correlation between vitamin D and growth hormone (GH)-insulin-like growth factor 1 (IGF1) axis is documented, as of date, few and conflicting studies have prospectively analyzed vitamin D before and after GH treatment. Our aim was to evaluate as to how the condition of GH deficiency (GHD) or GH treatment influences vitamin D in children. METHODS: Eighty Sicilian GHD children (M/F 58/22; mean age 10.3 years), grouped according to the season of evaluation in group A (June-September; 41 children) and group B (November-February; 39 children), were evaluated at baseline and after 12 months of GH treatment. RESULTS: Twenty-eight children (35 %) were vitamin D insufficient an…

Malemedicine.medical_specialtyAdolescentHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentComorbidityGrowth hormoneGrowth hormone deficiencySettore MED/13 - EndocrinologiaYoung AdultEndocrinologyHypovitaminosisInternal medicinemedicineVitamin D and neurologyPrevalenceHumansChildDwarfism Pituitaryvitamin D growth hormoneHigh prevalencebusiness.industryHuman Growth HormoneGrowth factorInfantmedicine.diseaseVitamin D DeficiencyEndocrinologyTreatment OutcomeChild PreschoolGh treatmentFemalebusinessGH Deficiency
researchProduct

Glucose Metabolism in Children With Growth Hormone Deficiency

2018

Background: The growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis has a fundamental impact on glucose metabolism. Therefore, both untreated GH deficiency (GHD) and GH treatment (GHT) may be associated with some metabolic alterations, although the abnormalities of glucose metabolism have been investigated by relatively few studies as main outcomes. Aim: The present review summarizes the available data on glucose metabolism in children with GHD, providing an overview of the current state of the art in order better to clarify the real metabolic impact of GHD and GHT. Methods: Among all the existing studies, we evaluated all original studies that fulfilled our criteria for analysis …

medicine.medical_specialtyChildren; Glucose; Growth hormone; Insulin sensitivity; Metabolism; Endocrinology Diabetes and MetabolismEndocrinology Diabetes and MetabolismMini Review030209 endocrinology & metabolismCarbohydrate metabolismGrowth hormonelcsh:Diseases of the endocrine glands. Clinical endocrinologyReporting parametersGrowth hormone deficiencySettore MED/13 - EndocrinologiaFasting glucose03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologychildrenInternal medicinemedicineGlucose homeostasisinsulin sensitivityglucoselcsh:RC648-665business.industryMetabolismmedicine.diseaseEndocrinology030220 oncology & carcinogenesisgrowth hormonebusinessmetabolismFrontiers in Endocrinology
researchProduct

OCT is not useful for detection of minimal diabetic retinopathy in type 1 diabetes.

2009

Optical coherence tomography (OCT) has been proven useful in measuring retinal thickness (RT) in patients with diabetes, although with discordant results in different studies. We examined RT in patients with type 1 diabetes (T1D) with or without minimal diabetic retinopathy (MDR) to test whether OCT is able to identify early retinal changes and potential correlations with metabolic parameters. RT of 102 patients with T1D (53 females, 49 males, aged 27.03 +/- 7.4 years) and of 42 healthy controls was examined, with analysis of nine different sectors (fovea, four pericentral and four peripheral sectors). According to the results of basal fundus photography, patients were divided into two grou…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismGastroenterologyRetinaSettore MED/13 - EndocrinologiaYoung AdultEndocrinologyOptical coherence tomography (OCT) type 1 diabetes (T1D) minimal diabetic retinopathy (MDR)retinal thickness (RT)Predictive Value of TestsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinMacular edemaType 1 diabetesDiabetic Retinopathymedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoFundus photographyGeneral MedicineDiabetic retinopathymedicine.diseaseRadiographyEndocrinologyDiabetes Mellitus Type 1Predictive value of testsMicroalbuminuriaFemalebusinessMedical FutilityTomography Optical CoherenceRetinopathy
researchProduct

Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month re…

2018

OBJECTIVE Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement of anthropometric and metabolic parameters. The aim of the study was to evaluate the effects of DR-HC on insulin secretion and sensitivity and cardiometabolic risk, indirectly expressed by the visceral adiposity index (VAI). DESIGN AND PATIENTS Retrospective analysis of 49 patients, 13 with primary and 36 with secondary adrenal insufficiency (AI), respectively, on conventional glucocorticoid treatment at baseline and switched to DR-HC for 36 months. Overall, 24 patients had AI-pre-diabetes (impaired fasting glucose, impaired glucose tolerance and the combination), and 25 had AI-…

Blood Glucoseinsulin secretionmedicine.medical_specialtyWaistHydrocortisoneEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaImpaired glucose tolerancePrediabetic State03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusGlucose IntolerancemedicineAdrenal insufficiencyHumansplenadrenPrediabetesGlucocorticoidsHydrocortisoneRetrospective Studiesbusiness.industryAdrenal insufficiency; diabetes; dual-release hydrocortisone; insulin secretion; plenadren; Endocrinology Diabetes and MetabolismFastingImpaired fasting glucosemedicine.diseaseEndocrinologydiabetedual-release hydrocortisoneInsulin ResistanceWaist CircumferencebusinessGlucocorticoidmedicine.drugAdrenal InsufficiencyClinical endocrinology
researchProduct

Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment.

2018

Acromegaly is a rare disease due to chronic GH excess and to the consequent increase in IGF-1 levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. Indeed, chronic GH excess impairs insulin sensitivity, increases gluconeogenesis, reduces the glucose uptake in adipose tissue and muscle and alters pancreatic β cells function. As a consequence, glucose metabolism alterations are a very frequent complication in acromegaly patients, further contributing to the increased cardiovascular risk and mortality. Treatment modalities of acromegaly differently impact on glucose tolerance. Successful surgical treatment of acromegaly ameliorates glucose metabolism a…

medicine.medical_specialtyGlucose uptakeMini Reviewglucose metabolismEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismCarbohydrate metabolismpituitary tumorlcsh:Diseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiaImpaired glucose tolerance03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusAcromegalymedicineGlucose homeostasislcsh:RC648-665diabetesbusiness.industrymedicine.diseasePasireotideGHEndocrinologyimpaired glucose toleranceAcromegaly Diabetes GH Glucose metabolism IGF-1 Impaired glucose tolerance Pituitary tumor Endocrinology Diabetes and Metabolismchemistry030220 oncology & carcinogenesisPegvisomantAcromegalyIGF-1businessmedicine.drug
researchProduct

Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS

2017

Background and aims Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) recognize obesity and insulin resistance (IR) as common pathogenic background. We assessed 1) whether PCOS is a risk factor for steatosis, and 2) the impact, in PCOS patients, of IR and hyperandrogenism on steatosis and fibrosis. Methods We considered 202 consecutive Italian PCOS nondiabetic patients and 101 age-matched controls. PCOS was diagnosed applying the Rotterdam diagnostic criteria. Steatosis was diagnosed if hepatic steatosis index (HSI) >36, while fibrosis by using the FIB-4 score. As surrogate estimate of insulin sensitivity we considered the insulin sensitivity index (ISI). Free an…

0301 basic medicineSteatosisendocrine system diseasesPhysiologylcsh:MedicinePathology and Laboratory MedicineBiochemistryBody Mass IndexCytopathology0302 clinical medicineEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseMedicine and Health SciencesInsulinlcsh:ScienceMultidisciplinaryLiver DiseasesFatty liverMiddle AgedPolycystic ovaryLipidsCholesterolOncologyPhysiological Parameters030211 gastroenterology & hepatologyFemalePolycystic Ovary SyndromeResearch ArticleAdultmedicine.medical_specialtyGastroenterology and Hepatology03 medical and health sciencesInsulin resistanceInternal medicinemedicineHumansObesityRisk factorTriglyceridesDiabetic Endocrinologybusiness.industryFree androgen indexHyperandrogenismCholesterol HDLBody Weightlcsh:RCancers and NeoplasmsBiology and Life Sciencesmedicine.diseaseFibrosisHormonesFatty Liver030104 developmental biologyEndocrinologyAnatomical Pathologylcsh:QSteatosisInsulin ResistancebusinessHyperandrogenismGynecological TumorsDevelopmental Biologyinsulin resistance PCOS
researchProduct

Growth hormone and hematopoiesis: A retrospective analysis on a large cohort of children with growth hormone deficiency

2018

Objective: Few large-scale studies regarding the impact of GH deficiency (GHD) on hematopoiesis in children have been reported. Our aim was to investigate hematopoiesis indices in a large cohort of GHD children at diagnosis and during GH treatment (GHT) and any correlation with hormonal parameters. Design: Clinical and biochemical data of children with idiopathic GHD at diagnosis and annually up to 36 months of GHT were retrospectively evaluated. Overall, 255 children reached 12 months, 140 children 24 months and 86 children 36 months of follow-up during GHT. Results: At baseline, 18.4% of GHD children and 10.1% of controls showed normocytic anemia. GHD children showed lower hemoglobin (Hb)…

MalePediatricsmedicine.medical_specialtyAnemiaEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismSettore MED/13 - EndocrinologiaGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyHumansGrowth hormone treatmentMedicineHematopoiesiInsulin-Like Growth Factor IChildChildrenGrowth hormoneGrowth DisordersRetrospective StudiesHuman Growth Hormonebusiness.industryAnemiaNormocytic anemiamedicine.diseaseHematopoiesisGrowth hormone treatmentHaematopoiesisChild Preschool030220 oncology & carcinogenesisErythropoiesisFemaleGrowth hormone deficiencyHemoglobinbusinessHormoneGrowth Hormone & IGF Research
researchProduct

Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity

2019

Lacrimal gland (LG) involvement in patients with Graves ophthalmopathy (GO) has been considered as a potential cause of the associated GO symptoms and different studies demonstrated the LG involvement in patients with GO than healthy controls. The aim of this study was to evaluate LG involvement, through measurement of its herniation, using a magnetic resonance imaging (MRI) index, in patients with different GO activities. Thirty-two consecutive Caucasian patients affected by GO were enrolled and grouped in group A (16 with inactive GO, CAS < 3) and B (16 with active GO, CAS ≥ 3) according to their GO activity. All patients underwent clinical-endocrinological assessment, a complete ocular e…

AdultMalemedicine.medical_specialtyHerniaTrabLacrimal glandSeverity of Illness IndexGastroenterologySettore MED/13 - Endocrinologia030218 nuclear medicine & medical imagingGraves' ophthalmopathy03 medical and health sciencesMagnetic resonance imaging0302 clinical medicineInternal medicineHumansMedicineRadiology Nuclear Medicine and imagingStage (cooking)Lacrimal apparatuAgedmedicine.diagnostic_testSettore MED/30 - Malattie Apparato Visivobusiness.industryThyroidLacrimal ApparatusSettore MED/37 - NeuroradiologiaOrbital diseasesMagnetic resonance imagingGeneral MedicineMiddle AgedGraves ophthalmopathymedicine.diseasemedicine.anatomical_structure030220 oncology & carcinogenesisBiomarker (medicine)FemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessHormoneEuropean Radiology
researchProduct

Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency

2017

Purpose Patients with growth hormone deficiency (GHD) demonstrate an increased cortisol/cortisone ratio which could potentially explain the metabolic features of GHD, while GH treatment (GHT) could increase the cortisol metabolism. Methods In 35 children (27 M, mean age 10.1 years) with idiopathic GHD at baseline and after 12 months of GHT and in 25 controls, in addition to metabolic parameters, we assessed adrenal function by morning serum cortisol, its peak, and its area under the curve (AUCCOR) during insulin tolerance test (ITT). Results A cortisol peak <18 µg/dl was shown in 22 and 31% of GHD children at baseline and after GHT, respectively. At baseline, GHD children had lower fasting …

Malemedicine.medical_specialtyGHD adrenal insufficiencyCortisol awakening responseHydrocortisoneEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismSettore MED/13 - EndocrinologiaGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicineAdrenal GlandsmedicineHumansProspective Studies030212 general & internal medicineChildDwarfism PituitaryMorningHydrocortisoneHuman Growth Hormonebusiness.industryInsulin tolerance testPrognosismedicine.diseaseGrowth hormone secretionEndocrinologyCase-Control StudiesChild PreschoolFemaleAdrenal Cortex Function TestsInsulin ResistanceCortisonebusinessBiomarkershormones hormone substitutes and hormone antagonistsFollow-Up Studiesmedicine.drugJournal of Endocrinological Investigation
researchProduct

Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?

2014

ObjectiveDiabetes mellitus (DM) is one of the most frequent complications of Cushing's syndrome (CS). The aim of this study was to define the changes in insulin sensitivity and/or secretion in relation to glucose tolerance categories in newly diagnosed CS patients.DesignCross-sectional study on 140 patients with CS.MethodsA total of 113 women (80 with pituitary disease and 33 with adrenal disease, aged 41.7±15.7 years) and 27 men (19 with pituitary disease and eight with adrenal disease, aged 38.1±20.01 years) at diagnosis were divided according to glucose tolerance into normal glucose tolerance (CS/NGT), impaired fasting glucose and/or impaired glucose tolerance (CS/prediabetes), and diabe…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and Metabolismmedicine.medical_treatmentCushing's syndromeSettore MED/13 - EndocrinologiaPrediabetic StateImpaired glucose toleranceEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionGlucose IntoleranceDiabetes MellitusmedicineHumansInsulinPrediabetesCushing SyndromeRetrospective StudiesCushing DiabetesGlucose tolerance testhypercortisolismmedicine.diagnostic_testbusiness.industryInsulinGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseImpaired fasting glucoseDiabetes and MetabolismCross-Sectional StudiesPhenotypeEndocrinologyDiabetes Mellitus Type 2diabeteFemaleInsulin ResistanceMetabolic syndromebusinessAdult; Cross-Sectional Studies; Cushing Syndrome; Diabetes Mellitus Type 2; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydrocortisone; Insulin; Insulin Resistance; Male; Middle Aged; Phenotype; Prediabetic State; Retrospective Studies; Endocrinology Diabetes and Metabolism; EndocrinologyType 2European Journal of Endocrinology
researchProduct

The Daily Consumption of Cola Can Determine Hypocalcemia: A Case Report of Postsurgical Hypoparathyroidism-Related Hypocalcemia Refractory to Supplem…

2017

The consumption of soft drinks is a crucial factor in determining persistent hypocalcemia. The aim of the study was to evaluate the biochemical mechanisms inducing hypocalcemia in a female patient with usual high consumption of cola drink and persistent hypocalcemia, who failed to respond to high doses of calcium and calcitriol supplementation. At baseline and after pentagastrin injection, gastric and duodenal secretion samples were collected and calcium and total phosphorus concentrations were evaluated. At the same time, blood calcium, total phosphorus, sodium, potassium, chloride, magnesium concentrations and vitamin D were sampled. After intake of cola (1 L) over 180 min, gastric and du…

0301 basic medicinemedicine.medical_specialtyCalcitriolEndocrinology Diabetes and MetabolismSodiumPotassiumchemistry.chemical_elementCase Report030209 endocrinology & metabolismCalciumhypocalcemiacalcium absorption; cola; hyperphosphatemia; hypocalcemia; hypoparathyroidismCola (plant)calcium absorptionSettore MED/13 - Endocrinologia03 medical and health sciencesEndocrinology0302 clinical medicinehypocalcemia cola hypoparathyroidism hyperphosphatemia calcium absorptionInternal medicinemedicinehyperphosphatemiaSettore CHIM/02 - Chimica FisicaCalcium metabolismbiologyChemistryhypoparathyroidismcolaSettore CHIM/06 - Chimica Organicamedicine.diseasebiology.organism_classificationSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatrichePentagastrin030104 developmental biologyEndocrinologyHypoparathyroidismmedicine.drug
researchProduct

Correlation between severity of growth hormone deficiency and thyroid metabolism and effects of long-term growth hormone treatment on thyroid functio…

2013

&lt;b&gt;&lt;i&gt;Background/Aim:&lt;/i&gt;&lt;/b&gt; The significance of changes in thyroid function in children during growth hormone (GH) treatment remains uncertain. We aimed to evaluate the impact of GH replacement on thyroid status in children with idiopathic GH deficiency (GHD). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Data of 105 GHD children (82 M, 23 F; aged 11.13 years) during a 36-month follow-up were analyzed. At diagnosis the areas under the curve of GH (AUC&lt;sub&gt;GH&lt;/sub&gt;) were calculated during a GH-releasing hormone + arginine (GHRH-Arg) and insulin tolerance test. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; A significant &amp;#x0394;fT&lt;sub&gt;3&lt;/su…

Malemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismThyroid GlandArginineGrowth Hormone-Releasing HormoneGrowth hormone deficiencythyroidSettore MED/13 - Endocrinologiagrowth hormone; thyroidEndocrinologyInternal medicineMedicineHumansskin and connective tissue diseasesChildRetrospective StudiesTriiodothyroninebusiness.industryHuman Growth HormoneThyroidMetabolismGrowth hormone–releasing hormonemedicine.diseaseGrowth hormone treatmentEndocrinologymedicine.anatomical_structurePediatrics Perinatology and Child Healthgrowth hormoneTriiodothyronineFemalesense organsThyroid functionbusinessHormoneHormone research in paediatrics
researchProduct

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

2018

Abstract Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored. Current options include new pituitary surgery and/or radiosurgery, or alternative medical treatment with SRLs high dose regimens, pegvisomant (PEG) as monotherapy, or combined therapy with the addition of PEG or cabergoline to SRLs. A new pharmacological approach includes pasireotide, a second-generation SRL approved for patients who do not adequately respond to surgery and/or for whom surgery is not an option. No reports on efficacy and safety of combined therapy with pasireotide and p…

OncologyAdultMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPegvisomant030209 endocrinology & metabolismCase ReportAntineoplastic Agentslcsh:Diseases of the endocrine glands. Clinical endocrinologyRadiosurgerySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCombined treatmentCabergolineInternal medicineAcromegalymedicineHumansErgolinesSalvage TherapyCotreatmentlcsh:RC648-665Medical treatmentSomatostatin receptorbusiness.industryHuman Growth HormoneGeneral Medicinemedicine.diseasePrognosisResistantPasireotideHormonesPasireotidechemistry030220 oncology & carcinogenesisPegvisomantAcromegalyDrug Therapy CombinationAcromegaly; Cotreatment; Pasireotide; Pegvisomant; ResistantbusinessSomatostatinmedicine.drugBMC Endocrine Disorders
researchProduct

Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis

2018

Abstract Background Idiopathic type 1 diabetes mellitus (IDM) is characterized by an onset with insulinopenia and ketoacidosis with negative β-cell autoimmunity markers and lack of association with HLA. The aim of the study is to compare the clinical and metabolic parameters, the macro and microvascular complications, the adipose tissue dysfunction and the insulin secretion and sensitivity indexes in patients with IDM and autoimmune type 1 diabetes mellitus (ADM) at clinical onset. Methods Thirty patients with IDM and 30 with ADM, matched for age and gender, were retrospectively analyzed. BMI, waist circumference, lipids, glycemia, HbA1c, insulin requirement, glutamic oxaloacetic and glutam…

medicine.medical_specialtyType 1 diabetemedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissue030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologyCardiovascular risk factorSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusmedicineInternal Medicinec-Peptideslcsh:RC620-627Cardiovascular risk factorsType 1 diabetesC-Peptidebusiness.industryInsulinResearchInsulin secretionInsulin resistancemedicine.diseaseKetoacidosislcsh:Nutritional diseases. Deficiency diseasesType 1 diabetesSteatosisC-Peptides; Cardiovascular risk factors; Insulin resistance; Insulin secretion; Type 1 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolismbusiness
researchProduct

Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth h…

2014

Purpose: To evaluate the performance of various indexes of insulin sensitivity and secretion and to identify the most useful indicator of deterioration of glucose metabolism in a cohort of children with growth hormone (GH) deficiency (GHD) during GH treatment. Methods: In 73 GHD children (55 M, 18 F; mean age 10.5 years) at baseline and after 12 months of treatment, we evaluated a number of surrogate indexes of insulin secretion and sensitivity. In a subgroup of 11 children we also performed an euglycemic hyperinsulinemic clamp. Results: After 12 months, a significant increase in fasting glucose (p < 0.001) and HbA1c levels (p < 0.001) was documented, despite all children remained with a no…

Blood GlucoseMalemedicine.medical_specialtyAdolescentHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentChildren; Glucose metabolism; Growth hormone treatment; Insulin secretion; Insulin sensitivity; Endocrinology Diabetes and Metabolism; EndocrinologyHypopituitarismCarbohydrate metabolismHypopituitarismSettore MED/13 - EndocrinologiaEndocrinologyInsulin resistanceInsulin-Secreting CellsInternal medicinemedicineHormone replacement therapy (male-to-female)HumansInsulinGrowth hormone treatmentChildDwarfism PituitaryChildrenGlucose metabolismGlucose tolerance testmedicine.diagnostic_testHuman Growth Hormonebusiness.industryInsulin secretionInsulinGlucose Tolerance TestInsulin sensitivitymedicine.diseaseGrowth hormone treatmentTreatment OutcomeEndocrinologyChild PreschoolConcomitantFemaleInsulin Resistancebusiness
researchProduct

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency.

2016

OBJECTIVE: GH treatment (GHT) can lead to glucose metabolism impairment through decreased insulin sensitivity and impaired pancreatic β-cell function, which are the two key components of the pathogenesis of diabetes. Therefore, in addition to insulin sensitivity, during GHT it is very important to perform a reliable evaluation of insulin secretion. However, conflicting data exist regarding the insulin secretion in children during GHT. C-peptide provides a more reliable estimate of β-cell function than insulin, but few studies evaluated it during GHT. Our aim was to assess the usefulness of C-peptide in the evaluation of insulin secretion in GH deficiency (GHD) children. DESIGN: In 48 GHD ch…

Male0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismBiologyGlucagonHypopituitarismGrowth hormone deficiencySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceInsulin-Secreting CellsDiabetes mellitusInternal medicineInsulin SecretionmedicineHumansInsulinC-peptide growth hormone deficiencyProspective StudiesInsulin-Like Growth Factor IChildGlucose tolerance testC-Peptidemedicine.diagnostic_testHuman Growth HormoneC-peptideInsulinFastingGlucose Tolerance TestGlucagonmedicine.diseaseHormonesGrowth hormone treatment030104 developmental biologyEndocrinologychemistryArea Under CurveCase-Control StudiesChild PreschoolFemaleInsulin Resistance
researchProduct

GHD come predittore di sindrome metabolica

2017

Il GH, la cui principale azione consiste nella stimolazione della crescita corporea, continua ad esercitare funzioni metaboliche in età adulta, per cui l’ormai riconosciuta “sindrome da deficit di GH (GHD) dell’adulto” configura un vero e proprio modello di sindrome metabolica (SM). La prevalenza di SM nel GHD è infatti significativamente più alta rispetto alla popolazione generale anche se ad oggi sono ancora limitati gli studi prospettici di lunga durata che hanno analizzato specificatamente la prevalenza di SM e delle sue individuali componenti in soggetti GHD. Le azioni metaboliche del GH sono tessuto-specifiche, esplicandosi prevalentemente a livello di fegato, tessuto adiposo, muscolo…

Pediatricsmedicine.medical_specialtybusiness.industryGH sindrome metabolicaMedicinebusinessSettore MED/13 - Endocrinologia
researchProduct

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Deg…

2018

Background: Cardiovascular disease is a frequent complication of type 1 diabetes (T1D). We evaluated the effectiveness of switching from glargine to degludec in reducing the cardiovascular risk factors, the Framingham risk score (FRS) and visceral adiposity index (VAI) in patients with T1D and autoimmune polyglandular syndrome (APS).Methods: We selected 66 T1D outpatients who had been on stable treatment with glargine for at least 5 years. Among them, 30 patients maintained glargine (group A), while 36 were switched to degludec (group B) for 12 months. At baseline and after 12 months of observation, clinical and metabolic parameters, insulin dose, 30-days blood glucose (BG) self monitoring,…

medicine.medical_specialtyWaistType 1 diabetetype 1 diabetesmedicine.medical_treatmentEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyGroup AGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologyGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineIn patientGlargineOriginal ResearchType 1 diabetesFramingham Risk Scorelcsh:RC648-665business.industryInsulinmedicine.diseaseCardiovascular riskInsulin therapyComplicationbusinessHypoglycaemiaDegludecFrontiers in Endocrinology
researchProduct

Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

2018

Introduction: Cushing’s disease (CD) is characterized by procoagulative profile. Treatment with cortisol-reducing medications might normalize the coagulation impairment potentially eliminating the risk of thromboembolic complications. Aim: The aim of this prospective study is to evaluate the effectiveness of 6–12 months of treatment with pasireotide (Signifor®, Novartis) 600 µg twice daily on coagulative factors in 21 patients (16 females, mean age 46 ± 12.2 years) with CD. Biochemical, hormonal (urinary free cortisol, UFC; late night salivary cortisol, LNSC; ACTH) and coagulative parameters as Protrombin time (PT), aPTT, factors VIII, IX and XI, antithrombin III, protein C, protein S, fibr…

Cortisol secretionAdultBlood GlucoseMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterologySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansProspective StudiesProspective cohort studyThromboprophylaxisPituitary ACTH HypersecretionBlood CoagulationClotting factorCoagulationbusiness.industryAnticoagulantCoagulation; Cushing’s disease; Pasireotide; Pituitary; Thromboprophylaxis; Endocrinology Diabetes and Metabolism; EndocrinologyCushing's diseaseCushing’s diseaseMiddle Agedmedicine.diseasePasireotidePasireotideDiabetes and MetabolismCoagulative necrosisTreatment OutcomechemistryPituitary030220 oncology & carcinogenesisConcomitantThromboprophylaxiFemaleBlood Coagulation TestsbusinessSomatostatinEndocrine
researchProduct

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin lev…

2013

OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease control and CAB dosage. DESIGN: This is a retrospective clinical-based therapy analysis. PATIENTS: Forty-three patients with prolactinoma (eight men, 35 women), aged 33·65 ± 11·23 years, were evaluated metabolically at baseline and after 12 months of CAB treatment. MEASUREMENTS: Body mass index (BMI), systolic and diastolic blood pressure, waist circumference (WC), lipid profile, haemoglobinA1c (…

AdultBlood GlucoseMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPituitary neoplasmSettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultEndocrinologyInsulin resistanceInternal medicineCabergolineMedicineHumansPituitary NeoplasmsProlactinomaErgolinesProlactinomaAdiposityRetrospective Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryInsulinmedicine.diseaseLipidsProlactinBlood pressureEndocrinologyDopamine AgonistsMetabolomeFemaleInsulin ResistanceWaist CircumferencebusinessLipid profileBody mass indexmedicine.drugClinical endocrinology
researchProduct

Relative Hypoleptinemia in poor controlled patients with Type 1 Diabetes

2007

AdultBlood GlucoseLeptinMalemedicine.medical_specialtyTYPE 1 DIABETES HYPOLEPTINEMIAEndocrinology Diabetes and MetabolismClinical BiochemistryBlood PressureFatty Acids NonesterifiedBiochemistryBody Mass IndexSettore MED/13 - EndocrinologiaEndocrinologyInternal medicineMedicineHumansProspective StudiesGlycated HemoglobinType 1 diabetesbusiness.industryBiochemistry (medical)General Medicinemedicine.diseaseCholesterolDiabetes Mellitus Type 1FemaleInsulin Resistancebusiness
researchProduct

Direct and indirect effects of Growth Hormone Deficiency (GHD) on lung function in children: A mediation analysis

2018

Background: Studies on pulmonary function tests (PFTs) in Growth Hormone Deficiency (GHD) children are lacking. The aims of this study were: (i) to investigate PFTs in GHD pre-pubertal children with respect to Controls, before starting Growth Hormone Therapy (GHT) (T0); (ii) to evaluate changes of PFTs in GHD vs Controls, after 1-year GHT (T1). Forboth aims the mediation analysis (MA) was applied to evaluate the extent to which the relationship between GHD and PFTs could be ascribed to a height-mediated (indirect) or a GH direct effect. Methods: 47 pre-pubertal GHD children (aged 5–14 years) underwent PFTs at T0 and T1. At T0, 47 healthy children matched for age and sex were enrolled as Contr…

MalePulmonary and Respiratory MedicineAdolescentFunctional Residual CapacityVital CapacityPhysiology030209 endocrinology & metabolismGrowth hormoneAge and sexPulmonary function testingGrowth hormone deficiency03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineForced Expiratory VolumeStatistical analysesmedicineHumansChildDwarfism PituitaryLungChildrenStatistical softwareLung functionCarbon MonoxideHuman Growth HormoneNegotiatingbusiness.industryChildren Growth-hormone-deficiency Lung function tests Mediation analysisTotal Lung CapacityGrowth-hormone-deficiencymedicine.diseaseRespiratory Function TestsResidual VolumeItaly030228 respiratory systemGrowth HormoneLung function testsMediation analysisFemalebusiness
researchProduct

Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency

2018

Objective: Data about the impact of growth hormone treatment (GHT) on insulin sensitivity in children are quite controversial, due to the different surrogate indices that have been used. Design: We evaluated insulin sensitivity through the euglycemic hyperinsulinemic clamp, considered the gold standard technique, in 23 children affected by growth hormone deficiency (GHD) at baseline and after 12. months of GHT and in 12 controls with short stature at baseline, and we compared the clamp-derived index (M-value) with the most commonly used surrogate index of insulin sensitivity, as ISI Matsuda, and with circulating plasma markers of insulin sensitivity, as adiponectin and resistin levels. Resu…

Malemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismShort statureGrowth hormone deficiencySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGlucose IntolerancemedicineHumansResistinProspective StudiesChildGrowth DisordersEuglycemic hyperinsulinemic clampAdiponectinHuman Growth Hormonebusiness.industryGrowth hormone deficiency; Hyperinsulinemic clamp; Insulin sensitivity; Endocrinology Diabetes and Metabolism; EndocrinologyInsulin sensitivityHyperinsulinemic clampGold standard (test)Glucose Tolerance TestPrognosismedicine.diseaseInsulin sensitivityGrowth hormone treatmentEndocrinologyCase-Control Studies030220 oncology & carcinogenesisGlucose Clamp TechniqueFemaleResistinGrowth hormone deficiencyAdiponectinInsulin Resistancemedicine.symptombusinessBiomarkersFollow-Up Studies
researchProduct

Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly propose…

2015

Purpose To evaluate the clinical and metabolic behavior of children with isolated growth hormone (GH)-deficiency (GHD), grouped according to the new AIFA criteria for the appropriateness of use and reimbursement of GH treatment in children. Methods The clinical and metabolic data of 310 prepubertal children (220 M, 90 F; mean age 10.8 years) grouped, according to new AIFA note 39, into group A (No 181 with a peak of GH 10 µg/L) were retrospectively analyzed. Group A and B, diagnosed as having GHD, were treated with GH for at least 24 months, while group C was analyzed only at baseline. Results At baseline, group A showed higher waist circumference than B (p=0.031) and C (p=0.041), while no …

Malemedicine.medical_specialtyWaistAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGroup AGroup BGrowth hormone deficiencySettore MED/13 - Endocrinologiachemistry.chemical_compoundGovernment AgenciesEndocrinologyInternal medicineOutcome Assessment Health CaremedicineHumansChildDwarfism PituitaryGrowth hormone childrenbusiness.industryCholesterolInsulinmedicine.diseaseEndocrinologyItalychemistryChild PreschoolGrowth HormoneConcomitantPractice Guidelines as TopicGh treatmentFemalebusinessFollow-Up Studies
researchProduct

The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency

2016

The visceral adiposity index, based on anthropometric and metabolic parameters, has been shown to be related to adipose tissue function and insulin sensitivity. We aimed to evaluate the performance of the visceral adiposity index in adult patients with growth hormone deficiency. We enrolled 52 patients(mean age 51 ± 13 years) with newly diagnosed growth hormone deficiency and 50 matched healthy subjects as controls at baseline. At baseline and after 12 and 24 months of treatment we evaluated anthropometric measures, lipid profile, glucose and insulin during an oral glucose tolerance test, hemoglobin A1c, homeostasis model assessment estimate of insulin resistance, quantitative insulin sensi…

AdenomaAdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipose tissue030209 endocrinology & metabolism030204 cardiovascular system & hematologyGrowth hormone deficiencySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansPituitary NeoplasmsInsulin-Like Growth Factor IDwarfism PituitaryAdiposityAgedmedicine.diagnostic_testbusiness.industryInsulinQuantitative insulin sensitivity check indexMiddle Agedmedicine.diseaseGrowth hormone treatmentEndocrinologygrowth hormoneFemaleInsulin ResistanceWaist CircumferencebusinessLipid profile
researchProduct

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control

2018

Objective. In acromegaly, both lipotoxicity secondary to GH excess and insulin resistance have a significant impact on the liver. Ultrasonography has shown poor sensitivity in detecting hepatic steatosis and noninvasive methods have been proposed. We evaluated the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, and we correlated it with disease activity and insulin resistance. Design. Thirty-one patients with newly diagnosed acromegaly were studied at diagnosis and after 12 months of treatment with somatostatin receptor ligands. Methods. Glucose and insulin levels, surrogate estimates of insulin sensitivity, and hepatic steatosis through ultrasonography and …

0301 basic medicinemedicine.medical_specialtyArticle SubjectEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiaCorrelation03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicineAcromegalymedicinelcsh:RC648-665Endocrine and Autonomic SystemsSomatostatin receptorbusiness.industryhepatic steatosisInsulinmedicine.diseaseDisease control030104 developmental biologyLipotoxicitySteatosisbusinessResearch ArticleInternational Journal of Endocrinology
researchProduct

No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.

2013

Context: Women with type 1 diabetes mellitus (DM1) have a higher prevalence of polycystic ovary syndrome (PCOS) than the general population. Objective: The aim of this study was to clarify, in DM1 women with PCOS(PCOS-DM1), the influence of insulin therapy and glycemic control and evaluate the hormonal and phenotypic differences with age-matched and body mass index (BMI)-matched women with PCOS without diabetes. Design, Setting, and Patients: We evaluated 103 DM1 women with and without PCOS treated with intensive insulin therapy; 38 age-matched and BMI-matched women with PCOS without diabetes were compared in a cross-sectional study. Outcome Measurements: Clinical, anthropometric, and metab…

Adultmusculoskeletal diseasesPCOS Type 1 Diabetescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectClinical BiochemistryPopulationContext (language use)BiochemistryBody Mass IndexSettore MED/13 - EndocrinologiaYoung AdultEndocrinologyInternal medicineDiabetes mellitusPrevalencemedicineHumanseducationReproductive HistoryMenstrual cyclemedia_commoneducation.field_of_studyType 1 diabetesbusiness.industryPolycystic ovary syndrome (PCOS)Biochemistry (medical)nutritional and metabolic diseasesmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsCross-Sectional StudiesDiabetes Mellitus Type 1PhenotypeEndocrinologyCase-Control StudiesFemalebusinessBody mass indexPolycystic Ovary Syndrome
researchProduct

Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess

2017

The interplay between vitamin D and the growth hormone (GH)/insulin-like growth factor (IGF)-I system is very complex and to date it is not fully understood. GH directly regulates renal 1 alpha-hydroxylase activity, although the action of GH in modulating vitamin D metabolism may also be IGF-I mediated. On the other hand, vitamin D increases circulating IGF-I and the vitamin D deficiency should be normalized before measurement of IGF-I concentrations to obtain reliable and unbiased IGF-I values. Indeed, linear growth after treatment of nutritional vitamin D deficiency seems to be mediated through activation of the GH/IGF-I axis and it suggests an important role of vitamin D as a link betwee…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGrowth hormonevitamin D deficiencySettore MED/13 - EndocrinologiaGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineAcromegalyVitamin D and neurologyHumansMedicineInsulin-Like Growth Factor IVitamin DGrowth Disordersgrowth hormone vitamin DHuman Growth Hormonebusiness.industryGrowth factormedicine.diseaseGrowth hormone treatment030104 developmental biologyEndocrinologyAcromegalybusinessGH DeficiencyGrowth Hormone &amp; IGF Research
researchProduct

Difficoltà di identificazione della sindrome MEN2B ad esordio infantile: iter diagnostico.

2004

MEN2B syndromeSettore MED/13 - Endocrinologia
researchProduct

Adrenal incidentaloma: a new contributing factor in metabolic syndrome

2004

researchProduct

Insulino sensibilità ed insulinosecrezione nell’acromegalia in fase attiva.

2012

acromegalia
researchProduct

The relationship between metabolic syndrome and bone health: results of a retrospective gender specific female study.

2013

Metabolic SyndromeBone
researchProduct

Increased central corneal thickness in acromegalic patients.

2009

acromegaly
researchProduct

La valutazione retinica mediante Tomografia a Coerenza Ottica (OCT) nel diabete mellito tipo 1.

2008

OCT diabete tipo 1
researchProduct

IPOVITAMINOSI D ED EFFETTI BENEFICI DELLA TERAPIA SOSTITUTIVA CON GH SUI LIVELLI DI VITAMINA D IN BAMBINI AFFETTI DA DEFICIT DI GH

2014

GH VITAMINA D
researchProduct

EFFETTI METABOLICI DELLA TERAPIA SOSTITUTIVA CON GH IN BAMBINI AFFETTI DA DEFICIT DI GH DURANTE UN FOLLOW-UP DI 36 MESI

2014

GH METABOLISMO
researchProduct

Valutazione morfologica e funzionale surrenalica nell’acromegalia

2009

surrene acromegaliaSettore MED/13 - Endocrinologia
researchProduct

Changes in lipid profile and adipokine levels in GH deficient children during GH replacement therapy.

2006

GH growth hormone adipokineSettore MED/13 - Endocrinologia
researchProduct

Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients.

2012

Visceral adiposity Index
researchProduct

Adrenal incidentaloma: a new contributing factor in metabolic syndrome?

2004

adrenal incidentaloma
researchProduct

The lacrimal gland herniation role in the Graves’ orbitopathy

2017

To evaluate the LG involvement, through the measurement of the LG herniation by of magnetic resonance imaging (MRI), in patients with different GO activity

Settore MED/30 - Malattie Apparato VisivoSettore MED/36 - Diagnostica Per Immagini E Radioterapiagraves diseaseSettore MED/13 - Endocrinologia
researchProduct

No effect of GH/IGF-1 excess on adrenal glands in acromegalic patients

2007

researchProduct

Visfatin as a marker of adipose dysfunction and metabolic impairment in active acromegaly and its possible use during the follow-up

2015

Background Visfatin is an adipokine with insulin-mimetic and adipogenic effect related to insulin resistance (IR) and visceral adipose mass. Although acromegaly is characterized by both adipose dysfunction and IR, data on visfatin levels in acromegaly are very scarce and in the few existing studies no difference was reported between acromegalic patients and controls. Aim To evaluate the visfatin levels in acromegaly in relation to disease activity and type of treatment. Subjects and Methods Data of 56 patients (31 M, age 59 ± 12 yrs) were analyzed. Sixteen patients were newly diagnosed (ND), while the remaining were in therapy with somatostatin analogues (SA, 21), pegvisomant (PE, 12) and a…

acromegaly
researchProduct

GH-treatment improves growth and reduces the severity of fibrosis and hypertansaminasemia in a prepubertal child with sclerosant cholangiopathy

2011

GH
researchProduct

The adipose visceral dysfunction plays an important role in diabetes in Cushing disease.

2013

Background: Cushing disease (CD) is associated with increased morbidity and mortality caused by cardiometabolic alterations. Visceral Adiposity Index (VAI) expresses impaired adipose distribution and function which are related to the cardiometabolic risk. Aim: To evaluate in a cohort of CD patients the correlation between VAI and other parameters, such as gender, etiology, age, cortisol values measured in the morning (8 am) and at the midnight, urinary free cortisol (24h sample of urine, average of three samples) and glucose tolerance as normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), IFG+IGT and diabetes mellitus. Materials and methods: We …

Cushing
researchProduct

Systolic flow peak of inferior thyroid arteries in Graves’disease: A predictive parameter for the ophalmopathy development.

2004

researchProduct

Leptina e adiponectina nella valutazione del compenso glicometabolico in corso di diabete mellito di tipo 1 normopeso.

2006

leptina adiponectina diabete tipo 1Settore MED/13 - Endocrinologia
researchProduct

No effect of GH/IGF-1 excess on adrenal gland in Acromegalic patients.

2007

Acromegaly
researchProduct

Usefulness and safety of pasireotide in a case of acromegaly highly resistant to treatment.

2015

Background: Pasireotide is a novel somatostatin analogue with higher affinity to 4/5 known human somatostatin receptors subtypes. It could have utility in acromegalic patients not responding to available treatments, although a deterioration in glucose metabolism is described during its use. Case: We describe our experience in the management of a case of a 41 years-old man affected by mixed GH-PRL secreting pituitary macroadenoma (32 mm) high resistant to different treatments. At baseline, the patient showed GH nadir after OGTT 26 ng/ml, IGF-1 1369 ng/dl, PRL 2386 ng/ml, normal glucose tolerance (NGT) with HbA1c 5.9%. Eight months of pre-operative treatment with monthly lanreotide LA 120 mg …

acromegaly pasireotide
researchProduct

Increated central corneal thickness in acromegalic patients

2009

Acromegalia Spessore corneal IOP TonometriaSettore MED/30 - Malattie Apparato Visivo
researchProduct

Complete biochemical control and oituitary adenoma disappearance in a child with gigantism: efficay of octreotide therapy

2011

acromegalygigantismoctreotideSettore MED/13 - Endocrinologia
researchProduct

Revaluation of the clinical and metabolic behavior of GHD children during GH treatment according to newly proposed note 39 of the Italian Medicines A…

2015

Background The newly proposed note 39 of the Italian Medicines Agency (AIFA) revisited the diagnostic criteria of growth hormone deficiency (GHD) in children and, applying it, a percentage of children previously diagnosed as GHD may have received a wrong diagnosis and a unnecessary treatment, with potential clinical implications. Aim To evaluate the clinical and metabolic behavior of GH-treated children according to the new criteria of GHD diagnosis. Subjects and Methods: We retrospectively analyzed clinical and metabolic data of 310 prepubertal children (220 M, 90 F, age 10.8 ± 2.9 yrs) with short stature admitted to our section of Endocrinology during the years 2005-2014, having at least …

growth hormone AIFA note
researchProduct

Iter diagnostico "rapido" per un caso di MEN IIb in un giovane adolescente

2004

MEN IIB CARCINOMA MIDOLLARE DELLA TIROIDE FEOCROMOCITOMA GENE RETSettore MED/13 - Endocrinologia
researchProduct

Effect of the switch from conventional to “dual release hydrocortisone” in adult patients with primary and secondary adrenal insufficiency: a six-mon…

2015

idrocortisone
researchProduct

Trattamento con GH e metabolismo glucidico

2013

GH
researchProduct

Il c-peptide come marker principale nella storia naturale del Diabete di tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze.

2004

c-peptide
researchProduct

Alte dosi di cabergolina migliorano i parametri metabolici in pazienti affetti da prolattinoma.

2013

prolattinoma
researchProduct

Thyroid function during long-term GH treatment in children affected by idiopathic GH deficiency

2012

thyroid GH deficiency
researchProduct

Alterazioni del metabolismo glucidico determinate da eccesso di ormoni contro regolatori.

2010

Acromegalia
researchProduct

INSULIN SECRETION AND SENSITIVITY DURING PASIREOTIDE TREATMENT IN PATIENTS WITH RECURRENT CUSHING DISEASE: A CASE SERIES

2015

CUSHING DISEASE
researchProduct

Decreased regulatory CD4+CD25+ Treg cells in newly diagnosed type 1 diabetes

2003

diabetes
researchProduct

Maggior rischio cardiometabolico nelle donne affette da Cushing, anche in assenza di una franca Sindrome Metabolica.

2013

Cushing
researchProduct

EFFECT OF SWITCH FROM CONVENTIONAL GLUCOCORTICOIDS TO “DUAL RELEASE HYDROCORTISONE” (DR-HC) ON METABOLIC PROFILE AND QUALITY OF LIFE IN ADULT PATIENT…

2014

adrenal insufficiency
researchProduct

Clamp euglicemico iperinsulinemico e test al glucagone come utili strumenti di valutazione degli effetti metabolici della terapia sostitutiva con GH.

2014

Deficit GH
researchProduct

Il c-peptide come marker principale nella storia naturale del Diabete tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze

2004

researchProduct

Valutazione dell’insulino-sensibilità e della funzione adiposa viscerale nel diabete mellito tipo 1 autoimmune ed idiopatico.

2014

Diabete mellito tipo 1 idiopatico
researchProduct

The Daily Consumption of Cola Can Determine Hypocalcemia: A Case Report of Postsurgical Hypoparathyroidism-Related Hypocalcemia Refractory to Supplem…

2017

The consumption of soft drinks is a crucial factor in determining persistent hypocalcemia. The aim of the study is to evaluate the biochemical mechanisms inducing hypocalcemia in a female patient with usual high consumption of cola drink and persistent hypocalcemia, who failed to respond to high doses of calcium and calcitriol supplementation. At baseline and after pentagastrin injection, gastric secretion (Gs) and duodenal secretion (Ds) samples were collected and calcium and total phosphorus (Ptot) concentrations were evaluated. At the same time, blood calcium, Ptot, sodium, potassium, chloride, magnesium concentrations, and vitamin D were sampled. After intake of cola (1 L) over 180 min,…

Endocrinologyhypoparathyroidismcolahypocalcemiahyperphosphatemiacalcium absorptionFrontiers in Endocrinology
researchProduct

Metabolic effects of GH therapy in adults with GH deficiency: a 2 year prospective study

2015

Background Growth hormone deficiency (GHD) in adults is associated with adverse metabolic profile, while data about the metabolic effects of GH treatment are controversial. Aim To evaluate the metabolic influence of GH replacement in GHD. Subjects and Methods Data of 65 patients (35 M, age 54 ± 18 yrs) were analyzed. Before GH therapy and yearly up to 2 years we measured BMI, WC, visceral adiposity index (VAI), IGF-1, lipide profile, HbA1c and basal insulin-secretion (Homa-β) and -sensitivity (Homa-IR) indexes. Results No subject showed overt dysglycemia at baseline and during GH therapy. Hypertriglyceridemia was detected in 36 patients at baseline and in 31 and 20 respectively at 12 and 24…

Growth hormone
researchProduct

Buon compenso glicemico nei pazienti acromegalici affetti da diabete secondario.

2010

Acromegalia
researchProduct

La transizione del soggetto cronicamente malato dall’età pediatrica all’età adulta

2008

transizione
researchProduct

IL CONSUMO DI BEVANDE RICCHE DI ACIDO ORTOFOSFORICO COME FATTORE DI RISCHIO PER LO SVILUPPO DI IPOCALCEMIA: IL CASO DI UNA DONNA CON IPOPARATIROIDISM…

2014

IPOCALCEMIA
researchProduct

LA TERAPIA CON GH PEGGIORA L'INSULINO-SENSIBILITA' SENZA UN'ADEGUATA RISPOSTA PANCREATICA COMPENSATORIA IN BAMBINI AFFETTI DA DEFICIT DI GH DURANTE I…

2014

gh insulino-sensibilita'
researchProduct

GH-suppression test in acromegaly: comparison between OGTT and chocolate test

2005

Acromegaly
researchProduct

Alta prevalenza di Sindrome dell’ovaio policistico in donne diabetiche di tipo 1 in età fertile.

2012

diabete tipo 1 PCOS
researchProduct

Poor diagnostic value of the euglycemic-hyperinsulinemic clamp in the clinical assessment of insulin resistant women with PCOS.

2013

Insulin resistance (IR) per se and/or the ensuing compensatory hyperinsulinism, have been always considered as a key point in the pathogenesis of PCOS. Aim of our study was to evaluate which of these two aspects plays a key role in the pathogenesis of PCOS. Using a cross-sectional study design, 15 PCOS (Rotterdam criteria) and 16 age/BMI-matched control women (with suspect of IR) underwent clinical measures of IR after a 3-month withdrawal of insulin sensitizers and oral contraceptive pills. In an academic clinic setting, average glucose infusion rate (M-value) (during an euglycaemic–hyperinsulinaemic clamp), AUCinsulin and AUCglucose (during an Oral Glucose tolerance Test), HOMA-IR, ISI-Ma…

PCOS
researchProduct

LONG-TERM METABOLIC EFFECTS OF GH THERAPY IN CHILDREN WITH IDIOPATHIC GH DEFICIENCY

2013

Background Increased insulin levels during GH replacement therapy are often reported both in adults and in children with GH deficiency (GHD), although discordant data fully describe the behavior of metabolic parameters during GH therapy in children and overall the majority of published data are limited to the first 12 months of follow-up and in small populations. Aim To evaluate the long-term metabolic influences of GH replacement in a large selected cohort of prepubertal children with idiopathic GHD during GH therapy. Subjects and Methods Data of 194 prepubertal GHD children (150 M, 44 F; age 10.85 ± 2.77 yrs) were analyzed. Before GH therapy and yearly up to 36 months we measured body mas…

GH therapy
researchProduct